Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 11/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 11/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1669566 | 0.81 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CPOLBALOX15 | |
| SCHEMBL1669852 | 0.77 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CPOLBMAPT | |
| SCHEMBL6785544 | 0.75 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CMAPTALOX15 | |
| SCHEMBL1670164 | 0.70 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CPOLBMAPT | |
| SCHEMBL27260913 | 0.70 | PRKCQ (0.44) | PRKCQPRKCD | |
| SCHEMBL6056 | 0.70 | POLB (0.59) | ADRA2AADRA2BADRA2CPOLBMAPT | |
| SCHEMBL28802394 | 0.70 | PRKCQ (0.51) | PRKCQPRKCDMAPT | |
| SCHEMBL1670195 | 0.69 | KMT2A (0.48) | MAPTALOX15CYP1A2 | |
| SCHEMBL1670230 | 0.69 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CPOLBMAPT | |
| SCHEMBL10857050 | 0.68 | ADRA2A (0.54) | ADRA2AADRA2BADRA2CPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3584237-B1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-12-09 | — | — | EP | claimed |
| EP-2486009-B1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2019-08-21 | — | — | EP | claimed |
| US-20150209351-A1 | Alpha Adrenergic Receptor Modulators | ALLERGAN, INC. | 2015-07-30 | — | — | US | claimed |
| US-9040532-B2 | Alpha adrenergic receptor modulators | ALLERGAN, INC. (US) | 2015-05-26 | — | — | US | claimed |
| US-20120208821-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC (US) | 2012-08-16 | — | — | US | claimed |
| EP-2486009-A1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | Allergan, Inc. (US) | 2012-08-15 | — | — | EP | claimed |
| WO-2011044229-A1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2011-04-14 | — | — | WO | claimed |
| EP-3584237-B1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-2486009-B1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-9522150-B2 | Alpha adrenergic receptor modulators | ALLERGAN, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150209351-A1 | Alpha Adrenergic Receptor Modulators | ALLERGAN, INC. | 2015-07-30 | — | — | US | disclosed |
| US-9040532-B2 | Alpha adrenergic receptor modulators | ALLERGAN, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20120208821-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2486009-A1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | Allergan, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044229-A1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209351-A1 | Alpha Adrenergic Receptor Modulators | ADRB1, ADRB2, ADRA2C | ADRA2A 5/4885ADRA2B 9/4885ADRA2C 3/4885 |
| US-20120208821-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ADRB1, ADRB2, ADRA2C | ADRA2A 5/4885ADRA2B 9/4885ADRA2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.